Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Park Avenue Securities LLC

Park Avenue Securities LLC increased its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 42.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,955 shares of the biopharmaceutical company’s stock after purchasing an additional 2,358 shares during the quarter. Park Avenue Securities LLC’s holdings in Insmed were worth $549,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. V Square Quantitative Management LLC purchased a new stake in shares of Insmed in the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC increased its holdings in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the period. Blue Trust Inc. lifted its stake in Insmed by 2,348.8% during the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. purchased a new position in shares of Insmed during the third quarter worth $133,000.

Analyst Ratings Changes

INSM has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Bank of America raised their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Truist Financial restated a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Insider Activity at Insmed

In other news, insider Martina M.D. Flammer sold 1,384 shares of Insmed stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total transaction of $95,108.48. Following the sale, the insider now owns 100,165 shares in the company, valued at approximately $6,883,338.80. The trade was a 1.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,740 shares of company stock valued at $7,161,294 over the last three months. 4.60% of the stock is owned by corporate insiders.

Insmed Stock Performance

Shares of INSM stock opened at $77.84 on Friday. The company has a market cap of $13.93 billion, a P/E ratio of -14.03 and a beta of 1.12. The firm has a fifty day moving average price of $71.48 and a 200 day moving average price of $72.80. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same period in the prior year, the company posted ($1.10) earnings per share. The business’s quarterly revenue was up 18.1% on a year-over-year basis. Sell-side analysts predict that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.